Nexstim logo

Nexstim Plc issues shares in standby equity distribution agreement pursuant to the financing arrangement announced on 21 July 2016 , 28.11.2016

28 November 2016

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or the “Company”), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that, pursuant to the authorisations received at the Company's extraordinary general meeting on 18 August 2016 and the financing arrangement entered into with Bracknor Investment and the Finnish Innovation Fund Sitra which was announced on 21 July 2016, the Board of Directors of the Company has today resolved on issuing 4,109,223 new shares to Bracknor with a subscription price of EUR 999,999.96 based on the stand-by equity distribution agreement (SEDA). The Board of Directors of the Company has also decided to issue 999,371 treasury shares to the Company itself without consideration and list the afore mentioned shares. The new shares will be listed approximately on 1 December 2016. After the transfer the Company will have 3,218,445 treasury shares. After the issuance, the total number of registered shares in the Company will be 32,184,452.

 

NEXSTIM PLC

Martin Jamieson, Chairman and CEO

 

Further information is available on the website www.nexstim.com or by contacting:

 

Nexstim                                                                                                                                    +447715163942

Martin Jamieson, Chairman and CEO                                                   martin.jamieson@nexstim.com

                                                                                                                                                                                

UB Securities Oy (Certified Adviser)                                                                         +358 (0)9 2538 0246

 

Consilium Strategic Communications                                                                     +44 (0)20 3709 5700

Mary-Jane Elliott / Ivar Milligan                                                           nexstim@consilium-comms.com

 

About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

Back to Press Releases